Collaborate With CatenaBio in
Pioneering Precision
Conjugation Technology

CatenaBio’s technology is the first-ever precision configurable conjugation reaction making use of only native amino acids. The candidates for biotherapeutic fusions range from small molecules and nucleic acids to whole enzymes and whole cells. If you’re imagining protein or enzyme conjugation in your industry, please reach out to us.

Imagination should be the only limit to creating biological therapeutics. Marco Lobba, PhD, CatenaBio CEO and co-founder

Let's Talk

Connect with us for access to our investor deck to delve deeper into our transformative program.

Message frequency may vary. You may opt out at any time. Terms and Conditions and Privacy Policy